Braveheart Bio closed a $185 million financing to launch registration‑enabling studies of a hypertrophic cardiomyopathy candidate licensed from Jiangsu Hengrui. The Series A attracted top biotech investors and named Biogen’s CEO as chair of the board, positioning the startup to run global late‑stage trials next year. The deal highlights continued investor appetite for well‑positioned cardiovascular programs and the ongoing strategy of Western startups licensing late‑stage assets from large Chinese developers to accelerate global development.